IntroductionCOVID 19 is still a challenge in pediatrics due to variety of symptoms and different presentationsAimTo describe clinical, laboratorial and treatment of confirmed COVID-19 pediatric admitted in hospitals.MethodsA retrospective study was conducted in children (0-18 years), admitted between March and November 15, 2020, with confirmed COVID-19 by reverse transcription polymerase chain reaction or serological tests. Clinical data about symptoms, laboratorial exams and treatments were analysed. Patients were evaluated according predominant (PRS) or non-predominant respiratory symptoms (non-PRS)ResultsSixty-four patients were evaluated, being the median age 5.6 years. Forty-seven (73.4%) children were admitted with PRS and 17 (26.4%) with non-PRS. The main symptoms in the PRS group were fever in 74.5% of children and cough in 66%; and fever in 76.5% and edema/cavitary effusion in 29.4% in the non-PRS group. The median of C-reactive protein (in mg/dl) was 2.5 in the PRS group and 6.1 in the non-PRS group. Antibiotics were used in 85.1% of the PRS group and 94.1% of non-group. Comorbidity was present in 30/47 (63.8%) of PRS group and 8/17 (47.1%) of non-PRS group (p=0.22). Length of stay until 7 days in patients with comorbidity was present in 27/64 (42.1%) and more than 7 days in 11/64 (17.1%) (p= 0.2)ConclusionNon-PRS represented more than one quarter of admitted patients. Fever was the main symptom detected, elevated CRP was frequent and antibiotics were commonly prescribed. Comorbidity was found in both groups and his presence was not associated with a longer length of stay.

Objective: To evaluate COVID-19 vaccination status in admitted children during the OMICRON variant circulation. Design: Observational retrospective study. Patients with confirmed COVID-19 were compared in two different periods: 2020-2021 when full COVID-19 vaccine were not completed for adolescents between 12 and 18 years and 2022, when Pfizer-BioNTech vaccine full scheme were completed for children older 12 years Setting: Two paediatric hospitals in Rio de Janeiro, city Patients: Children aged <18 years with confirmed COVID-19. Intervention: None Main outcome: Vaccination status for COVID-19 at the admission. Results: Three-hundred patients were admitted with confirmed COVID-19, being 240 in 2020-2021, and 60 in 2022. The distribution of patients according to the age-groups were: 0-2 years (33.3% in 2020-2021 and 53.4% in 2022), 2-5 years (21.7% in 2020-2021 and 10% in 2022), 5-11 years (29.2% in 2020-2021 and 28.3% in 2022) and 12-18 years (15.8% in 2020-2021 and 8.3% in 2022) ( p= 0.015). The median of lenght of stay was 6 days in 2020-2021 and 5 days in 2022 (p=0.036). We verified 6 deaths and in the first period of analysis and 1 death in the second one (p=0.777). Of 60 children admitted in 2022, fifty-eigth (96.7%) not received the full scheme of COVID-19 vaccine available Conclusions: We verified in a real world condition ability of Pfizer-BioNTech vaccine in avoid hospitalization in children older than 12 years